Business
SVN-015 accepted into US NIDA funded programme
Solvonis Therapeutics plc announced that its novel compound SVN-015 has been accepted into the US National Institute on Drug Abuse's Addiction Treatment Discovery Program for methamphetamine and cocaine addiction, with NIDA funding early preclinical safety and efficacy studies. Successful completion could lead to non-dilutive NIH research grants of up to $3 million annually for five years, potentially funding human clinical trials. This marks an expansion of Solvonis' research into stimulant addictions, areas with significant unmet medical need and no approved drug treatments, impacting an estimated 3.0-3.2 million individuals across major markets. Disclaimer*
About this update from Solvonis Therapeutics Plc
[{"type":"text","content":"\n\nSolvonis Therapeutics plc\n(\"Solvonis\" or the \"Company\")\n \nSolvonis' Novel Compound SVN-015 Accepted into US NIDA-Funded Addiction Treatment Discovery Program for Methamphetamine and Cocaine Addiction\n \nSolvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (CNS) disorders, announces that its novel AI-discovered compound, SVN-015, targeting methamphetamine and cocaine use disorders, has been accepted into the US National Institute on Drug Abuse's (\"NIDA\") Addiction Treatment Discovery Program (\"ATDP\"). Under the programme, NIDA, part of the US National Institutes of Health (\"NIH\"), will fund and conduct early preclinical evaluation of SVN-015.\n \nProgramme Overview\nIn the first stage of the programme, NIDA will fund and carry out in vitro predictive safety studies on SVN-015 to assess potential cardiovascular risks. These tests are the normal first step in the development of any new medicine. If the results are supportive, SVN-015 could advance into ATDP efficacy studies in validated preclinical models of methamphetamine and cocaine addiction.\n \nIf the efficacy studies are successful, Solvonis would be well positioned to compete for a non-dilutive NIH research grant, which can provide up to US$3 million per year for as long as five years. These grants are competitive, but completion of early preclinical studies would provide the type of safety and efficacy data needed to support Solvonis' grant application. This creates a potential pathway from funded NIDA preclinical work through to potential NIH-funded clinical trials in humans.\n \nStrategic Significance\nAcceptance of SVN-015 into the ATDP marks an important milestone for Solvonis as it expands the Company's research in addiction beyond alcohol use disorder (\"AUD\") into stimulant addictions - specifically methamphetamine and cocaine - which remain among the most severe psychiatric conditions with no approved drug treatments.\n \nProfessor David Nutt, Solvonis Chief Scientific Officer, commented \"Being accepted into NIDA's ATDP for SVN-015 is a major step forward for Solvonis. ATDP provides a pathway for evaluating the therapeutic potential of SVN-015, starting with early preclinical testing and, if successful, creating the opportunity...